Time for a low-risk DCIS trial: Harnessing public and patient involvement

摘要

An independent review, led by Professor Sir Michael Marmot, of the UK National Health Service's breast screening programme has examined the controversies about the benefits and harms of mammographic screening, including the suggestion that some women with screen-detected lesions could be overtreated. These concerns have focused mainly on low-grade ductal carcinoma in-situ (DCIS), the most benign end of the histological range of breast cancers.